Cat. #151883
Anti-Fbxo7 [HLA3]
Cat. #: 151883
Sub-type: Primary antibody
Unit size: 100 ug
Target: Fbxo7
Class: Polyclonal
Application: IHC ; IP ; WB
Reactivity: Human ; Mouse
Host: Rabbit
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Heike Laman
Institute: University College London (UCL)
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Fbxo7 [HLA3]
- Research fields: Cell biology;Genetics
- Clone: HLA3
- Tool sub type: Primary antibody
- Class: Polyclonal
- Conjugation: Unconjugated
- Molecular weight: ~59/~70 kDa
- Reactivity: Human ; Mouse
- Host: Rabbit
- Application: IHC ; IP ; WB
- Description: Recessive mutations in FBXO7/PARK15 cause an atypical EOPD. In certain cancers, the protein is highly expressed. These cell lines all express Fbxo7: U2OS, SHSY5Y, HEK293, Jurkat, SKOV3, HeLa, Ba-F3, Nalm6, C33A, MEL, HSPCs, MEFs.
- Immunogen: aa 499-522 of human Fbxo7 synthetic peptide coupled to KLH
- Recommended controls: Any cultured cell line grown in FBS
Target Details
- Target: Fbxo7
- Molecular weight: ~59/~70 kDa
- Tissue cell line specificity: Any cultured cell line grown in FBS
- Target background: Recessive mutations in FBXO7/PARK15 cause an atypical EOPD. In certain cancers, the protein is highly expressed. These cell lines all express Fbxo7: U2OS, SHSY5Y, HEK293, Jurkat, SKOV3, HeLa, Ba-F3, Nalm6, C33A, MEL, HSPCs, MEFs.
Applications
- Application: IHC ; IP ; WB
Handling
- Format: Liquid
- Unit size: 100 ug
- Shipping conditions: Shipping at 4° C
References
- Burchell et al. 2013. Nat Neurosci. 16(9):1257-65. PMID: 23933751.
- The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy.
- Meziane el et al. 2011. J Cell Sci. 124(Pt 13):2175-86. PMID: 21652635.
- Knockdown of Fbxo7 reveals its regulatory role in proliferation and differentiation of haematopoietic precursor cells.
- Laman et al. 2005. EMBO J. 24(17):3104-16. PMID: 16096642.
- Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6.
